Smart-money series

Latest Politician Trades

Every disclosed Senate and House stock trade, freshest first. Click a politician for their full profile; click a filing for the original PTR.

DatePoliticianAssetTypeAmountFiling
2020-01-13Greg GianforteCHKP · Check Point Software Technologies Ltd. - Ordinary SharesSell$15k – $50k
2020-01-03Greg GianforteCHKP · Check Point Software Technologies Ltd. - Ordinary SharesBuy$15k – $50k
2019-06-24Donna ShalalaCHKP · Check Point Software Technologies Ltd. - ordinary SharesSell$15k – $50k
2019-02-15Donna ShalalaCHKP · Check Point Software Technologies Ltd. - ordinary SharesBuy$1k – $15k
2018-12-27Greg GianforteCHKP · Check Point Software Technologies Ltd. - Ordinary SharesBuy$15k – $50k
2018-10-01Katherine M. Clark · D-MACHKP · Check Point Software Technologies ltd. - Ordinary SharesSell$1k – $15k
2018-04-26James M InhofeCHKP · Check Point Software Technologies Ltd.Sell$50k – $100kPTR
2017-12-07Pete Sessions · R-TXCHKP · Check Point Software Technologies ltd. - Ordinary SharesSell$15k – $50k
2017-02-21Josh Gottheimer · D-NJCHKP · Check Point Software Technologies Ltd. - ordinary SharesBuy$1k – $15k
2017-01-26James M InhofeCHKP · Check Point Software Technologies Ltd.Buy$50k – $100kPTR
2016-10-11Katherine M. Clark · D-MACHKP · Check Point Software Technologies ltd. - Ordinary SharesBuy$1k – $15k
2016-08-25Susan A. DavisCHKP · Check Point Software Technologies ltd. - Ordinary SharesSell$15k – $50k
2016-06-14Pete Sessions · R-TXCHKP · Check Point Software Technologies ltd. - Ordinary SharesSell$1k – $15k
2015-08-25Pete Sessions · R-TXCHKP · Check Point Software Technologies ltd. - Ordinary SharesBuy$1k – $15k
2015-05-06Pete Sessions · R-TXCHKP · Check PT Software TECH FBuy$1k – $15k
2015-03-31Susan A. DavisCHKP · Check Point Software Technologies ltd. - Ordinary SharesBuy$15k – $50k
2015-01-27Thomas MacArthurCHKP · Check Point Software Technologies Ltd. - ordinary SharesSell$15k – $50k

Source: US House & Senate periodic transaction reports (PTRs). Educational only — not investment advice. See our methodology.